JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 153 filers reported holding JUNO THERAPEUTICS INC in Q2 2015. The put-call ratio across all filers is 2.17 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $3,533,000 | +0.1% | 77,286 | -1.8% | 0.00% | 0.0% |
| Q3 2017 | $3,529,000 | +64.6% | 78,683 | +9.7% | 0.00% | 0.0% |
| Q2 2017 | $2,144,000 | -20.4% | 71,749 | -40.9% | 0.00% | 0.0% |
| Q1 2017 | $2,693,000 | +298.4% | 121,392 | +238.4% | 0.00% | – |
| Q4 2016 | $676,000 | +11.0% | 35,876 | +76.8% | 0.00% | – |
| Q3 2016 | $609,000 | +8.8% | 20,292 | +39.2% | 0.00% | – |
| Q2 2016 | $560,000 | +35.3% | 14,577 | +34.0% | 0.00% | – |
| Q1 2016 | $414,000 | -46.0% | 10,877 | -37.6% | 0.00% | – |
| Q4 2015 | $767,000 | -43.8% | 17,422 | -48.0% | 0.00% | -100.0% |
| Q3 2015 | $1,364,000 | +162.3% | 33,534 | +244.3% | 0.00% | – |
| Q2 2015 | $520,000 | -31.6% | 9,739 | -22.2% | 0.00% | – |
| Q1 2015 | $760,000 | +34.3% | 12,526 | +15.5% | 0.00% | – |
| Q4 2014 | $566,000 | – | 10,847 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 25,948,799 | $1,132,937,000 | 100.00% |
| Biomark Capital Management Co. LLC | 1,602,562 | $70,465,000 | 85.76% |
| Omega Fund Management, LLC | 1,229,512 | $54,062,000 | 30.09% |
| Clarius Group, LLC | 218,942 | $9,626,000 | 2.93% |
| BB BIOTECH AG | 1,305,000 | $57,381,000 | 1.62% |
| Casdin Capital, LLC | 17,500 | $769,000 | 0.68% |
| Rock Springs Capital Management LP | 197,001 | $8,662,000 | 0.66% |
| BENNETT LAWRENCE MANAGEMENT L L C/NY | 38,850 | $1,708,000 | 0.55% |
| ArrowMark Colorado Holdings LLC | 383,749 | $16,873,000 | 0.46% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 68,848 | $3,027,000 | 0.38% |